Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$6.12 USD
+0.20 (3.38%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $6.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Recursion Pharmaceuticals, Inc. [RXRX]
Reports for Purchase
Showing records 1 - 20 ( 87 total )
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Digital Biology Tech- Enabled Drug Discovery Initiation
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Business Updates Bolster Digital Chemistry Drug Development Capabilities
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Completed Phase 1 Study for REC-3964 with Phase 2 Proof-of- Concept Trial Expected to Initiate in 2024
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Recursion Pharmaceuticals, Inc.
Industry: Medical - Drugs
Positive Business Updates: New DataBase of Predictions + Drug Development Pipeline
Provider: KeyBanc Capital Markets
Analyst: Research Department